Brawn Biotech
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Jan 5 (Reuters) - Brawn Biotech Ltd BRAW.BO:
POOJA PANDEY RESIGNS AS CFO OF BRAWN BIOTECH
Source text: ID:nBSE1GrbWN
Further company coverage: BRAW.BO
(([email protected];))
Jan 5 (Reuters) - Brawn Biotech Ltd BRAW.BO:
POOJA PANDEY RESIGNS AS CFO OF BRAWN BIOTECH
Source text: ID:nBSE1GrbWN
Further company coverage: BRAW.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Brawn Biotech do?
Brawn Biotech Ltd is a pharmaceutical company engaged in manufacturing tablets, capsules, and oral syrups across various categories including Analgesics, Antibiotics, and Cardiovascular drugs.
Who are the competitors of Brawn Biotech?
Brawn Biotech major competitors are Amraworld Agrico, Amanaya Ventures, Muzali Arts, EVOQ Remedies, Voltaire Lsg. & Fin., Gujarat Metal. Coal, Triveni Enterprises. Market Cap of Brawn Biotech is ₹6 Crs. While the median market cap of its peers are ₹6 Crs.
Is Brawn Biotech financially stable compared to its competitors?
Brawn Biotech seems to be less financially stable compared to its competitors. Altman Z score of Brawn Biotech is 1.09 and is ranked 6 out of its 8 competitors.
Does Brawn Biotech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Brawn Biotech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Brawn Biotech allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Brawn Biotech balance sheet?
Brawn Biotech balance sheet is weak and might have solvency issues
Is the profitablity of Brawn Biotech improving?
The profit is oscillating. The profit of Brawn Biotech is ₹0.94 Crs for TTM, -₹1.7 Crs for Mar 2025 and -₹1.24 Crs for Mar 2024.
Is the debt of Brawn Biotech increasing or decreasing?
Yes, The net debt of Brawn Biotech is increasing. Latest net debt of Brawn Biotech is -₹0.28 Crs as of Mar-26. This is greater than Mar-25 when it was -₹0.37 Crs.
Is Brawn Biotech stock expensive?
Brawn Biotech is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Brawn Biotech is 6.38, while 3 year average PE is 1.15. Also latest EV/EBITDA of Brawn Biotech is 0.0 while 3yr average is 4.92.
Has the share price of Brawn Biotech grown faster than its competition?
Brawn Biotech has given better returns compared to its competitors. Brawn Biotech has grown at ~14.79% over the last 3yrs while peers have grown at a median rate of -8.99%
Is the promoter bullish about Brawn Biotech?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Brawn Biotech is 52.94% and last quarter promoter holding is 52.94%.
Are mutual funds buying/selling Brawn Biotech?
The mutual fund holding of Brawn Biotech is stable. The current mutual fund holding in Brawn Biotech is 0.35% while previous quarter holding is 0.35%.